ArticleClinical and molecular hepatology2021
Metabolic disease as a risk of hepatocellular carcinoma.
Article in Clinical and molecular hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 27 citations in OpenAlex.
- Systemic hematologic, metabolic, and inflammatory dysregulation in liver cirrhosis and hepatocellular carcinoma: diagnostic utility of novel indices in an Egyptian cohort.BMC gastroenterology · 2026Article
- Integrative transcriptomic analysis reveals miR-26a-5p downregulation and a potential predictive gene signature for the progression of metabolic liver disease.Frontiers in cell and developmental biology · 2026Article
- Large duct primary sclerosing cholangitis with or without inflammatory bowel disease in Saudi patients.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2025Article
- Metabolic dysfunction-associated steatotic liver disease and hepatocellular carcinoma: Challenges in clinical practice.Clinical and experimental hepatology · 2025Review
- Biosocial Determinants of Health Among Patients with Chronic Liver Disease and Liver Cancer.Cancers · 2025Article
- Cytokine-Induced Killer Cell Immunotherapy Reduces Recurrence in Patients with Early-Stage Hepatocellular Carcinoma.Cancers · 2025Article
- Global, regional, and national burden of NASH related liver cancer in adults aged 45 and above: an analysis from the GBD 2021 and forecast to 2050.Frontiers in nutrition · 2025Article
- Traditional Chinese Medicine as a Tool for the Treatment of Hepatocellular Carcinoma by Targeting Pathophysiological Mechanism.Cancer management and research · 2025Review
- Burden of uterine cancer in China from 1990 to 2021 and 15-year projection: a systematic analysis and comparison with global levels.Reproductive health · 2024Article
- Review
- Reply to correspondence on "Metformin and statins reduce hepatocellular carcinoma risk in chronic hepatitis C patients with failed antiviral therapy".Clinical and molecular hepatology · 2024Article
- Nanoquercetin and Extracellular Vesicles as Potential Anticancer Therapeutics in Hepatocellular Carcinoma.Cells · 2024Review
- Hepatitis B-related hepatocellular carcinoma: classification and prognostic model based on programmed cell death genes.Frontiers in immunology · 2024Article
- Review
- Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990-2019: A DALY-based analysis of the Global Burden of Disease 2019 study.Clinical and molecular hepatology · 2023Article
- The emerging age-pattern changes of patients with hepatocellular carcinoma in Korea.Clinical and molecular hepatology · 2023Article
- Association between metabolic syndrome, C-reactive protein, and the risk of primary liver cancer: a large prospective study.BMC cancer · 2022Article
- Article
- The Importance of Metabolic Syndrome Status for the Risk of Non-Viral Hepatocellular Carcinoma: A Nationwide Population-Based Study.Frontiers in oncology · 2022Article
- Metformin and Dichloroacetate Suppress Proliferation of Liver Cancer Cells by Inhibiting mTOR Complex 1.International journal of molecular sciences · 2021Article
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.